Literature DB >> 20656483

Hsp90 inhibition: elimination of shock and stress.

Adam S Duerfeldt1, Brian S J Blagg.   

Abstract

The 90 kDa heat shock proteins (Hsp90) represent a class of molecular chaperones responsible for the maturation and stabilization of many oncogenic proteins. Disrupting the ability of ATP to bind and facilitate the operation of Hsp90 has emerged as a promising approach toward cancer chemotherapeutic development. While numerous Hsp90 inhibitory scaffolds have been identified, progress through the clinic has revealed many obstacles that should be addressed in future analogue development. Recent reports of the complications, pitfalls, and downstream effects associated with Hsp90 inhibition are discussed herein, in hopes of providing a reference that can be used to guide the future design of Hsp90 inhibitory scaffolds. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656483      PMCID: PMC3166208          DOI: 10.1016/j.bmcl.2010.06.108

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  68 in total

Review 1.  The future of antihormone therapy: innovations based on an established principle.

Authors:  K Parczyk; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  DNA adducts from chemotherapeutic agents.

Authors:  P D Lawley; D H Phillips
Journal:  Mutat Res       Date:  1996-08-17       Impact factor: 2.433

3.  Human heat shock protein gene polymorphisms and sudden infant death syndrome.

Authors:  R A Rahim; P A Boyd; W J Ainslie Patrick; R H Burdon
Journal:  Arch Dis Child       Date:  1996-11       Impact factor: 3.791

4.  Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

Authors:  K T Kelsey; D Ross; R D Traver; D C Christiani; Z F Zuo; M R Spitz; M Wang; X Xu; B K Lee; B S Schwartz; J K Wiencke
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.

Authors:  M N Benchekroun; E Schneider; A R Safa; A J Townsend; B K Sinha
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

Review 6.  NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.

Authors:  M Belinsky; A K Jaiswal
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 7.  Clinical pharmacokinetics of anti-metabolites.

Authors:  G J Peters; J H Schornagel; G A Milano
Journal:  Cancer Surv       Date:  1993

8.  Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.

Authors:  S A Fitzsimmons; P Workman; M Grever; K Paull; R Camalier; A D Lewis
Journal:  J Natl Cancer Inst       Date:  1996-03-06       Impact factor: 13.506

Review 9.  Monoclonal antibodies in the treatment of cancer.

Authors:  R O Dillman
Journal:  Crit Rev Oncol Hematol       Date:  1984       Impact factor: 6.312

10.  The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?

Authors:  N Robertson; I J Stratford; S Houlbrook; J Carmichael; G E Adams
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

View more
  11 in total

1.  Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

2.  Targeting the heat shock protein 90 dimer with dimeric inhibitors.

Authors:  Bhaskar Reddy Kusuma; Laura B Peterson; Huiping Zhao; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Med Chem       Date:  2011-08-23       Impact factor: 7.446

3.  Progesterone receptor chaperone complex-based high-throughput screening assay: identification of capsaicin as an inhibitor of the Hsp90 machine.

Authors:  Chaitanya A Patwardhan; Eyad Alfa; Su Lu; Ahmed Chadli
Journal:  J Biomol Screen       Date:  2014-09-02

4.  Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.

Authors:  Xiaokai Li; Sharan R Srinivasan; Jamie Connarn; Atta Ahmad; Zapporah T Young; Adam M Kabza; Erik R P Zuiderweg; Duxin Sun; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2013-11-14       Impact factor: 4.345

5.  Elucidation of the Hsp90 C-terminal inhibitor binding site.

Authors:  Robert L Matts; Anshuman Dixit; Laura B Peterson; Liang Sun; Sudhakar Voruganti; Palgunan Kalyanaraman; Steve D Hartson; Gennady M Verkhivker; Brian S J Blagg
Journal:  ACS Chem Biol       Date:  2011-05-17       Impact factor: 5.100

6.  Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Authors:  Sanil Bhatia; Daniela Diedrich; Benedikt Frieg; Heinz Ahlert; Stefan Stein; Bertan Bopp; Franziska Lang; Tao Zang; Tobias Kröger; Thomas Ernst; Gesine Kögler; Andreas Krieg; Steffen Lüdeke; Hana Kunkel; Ana J Rodrigues Moita; Matthias U Kassack; Viktoria Marquardt; Friederike V Opitz; Marina Oldenburg; Marc Remke; Florian Babor; Manuel Grez; Andreas Hochhaus; Arndt Borkhardt; Georg Groth; Luitgard Nagel-Steger; Joachim Jose; Thomas Kurz; Holger Gohlke; Finn K Hansen; Julia Hauer
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

7.  A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response.

Authors:  Jeanette R McConnell; Leslie A Alexander; Shelli R McAlpine
Journal:  Bioorg Med Chem Lett       Date:  2013-12-01       Impact factor: 2.823

Review 8.  Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

Authors:  S V Alarcon; M Mollapour; M-J Lee; S Tsutsumi; S Lee; Y S Kim; T Prince; A B Apolo; G Giaccone; W Xu; L M Neckers; J B Trepel
Journal:  Curr Mol Med       Date:  2012-11-01       Impact factor: 2.222

9.  Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.

Authors:  Nerea Rebolleda; Ignacio Losada-Fernandez; Gema Perez-Chacon; Raquel Castejon; Silvia Rosado; Marta Morado; Maria Teresa Vallejo-Cremades; Andrea Martinez; Juan A Vargas-Nuñez; Paloma Perez-Aciego
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

10.  A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.

Authors:  Adi Mehta; Leroy Shervington; Chinmay Munje; Amal Shervington
Journal:  Cancers (Basel)       Date:  2011-12-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.